| Etiology | Monitoring |
| Epidemiology | Prognosis |
| Diagnosis | Prevention |
| Treatment | Patient Education |
|
EBM for Student Health Home Page About EBM EBM Resources Specific Conditions/Diseases |
Etiology
No evidence is cited.
Epidemiology
No evidence is cited.
Diagnosis
Clinical Diagnosis
No evidence is cited.
Laboratory/X-ray Diagnosis
No evidence is cited.
Treatment
An OC containing 0.035 mg of ethinyl estradiol combined with the triphasic regimen of norgestimate (Ortho Tri-Cyclen) is a safe and effective treatment of moderate acne vulgaris in women with no known contraindication to OC therapy.
- Caveats
- Age group studied: 15-49y
- Type/size: RCT of 257 patients
- Population characteristics: Healthy females
- Outcome measures: Facial acne lesion counts, investigator's global assessment, subject's self-assessment, analysis of within-cycle variation (cycle 6) in lesion counts
- Citations
- Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ, Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris, J Am Acad Dermatol 1997 Nov;37(5 Pt 1):746-754 - From PubMed
- Also: Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL, Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: arandomized, placebo-controlled trial, Obstet Gynecol 1997 Apr;89(4):615-622 - From PubMed
Monitoring
No evidence is cited.
Prognosis
No evidence is cited.
Prevention
No evidence is cited.
Patient Education
The following patient education materials are consistent with the available evidence.
- Acne in Teens: Ways to Control It - From AAFP
- Acne - From MSU Student Health
- Acne Agony - From the FDA
- Rosacea and Its Treatment - From AAFP
Rev. 7/5/99
[Return to Top of Page]
This Web site developed and maintained by Robert J. Flaherty, MD.
Comments, additions and corrections are encouraged.